Surfactant alteration and replacement in acute respiratory distress syndrome

Respiratory Research

Table 2 Surfactant apoprotein content in patients with acute respiratory distress syndrome (ARDS) and in other subjects

	Pison et al. [24]^a		Gregory et al. [25]^b			Günther et al. [26]^a				Greene et al. [28]^a
Surfactant								ARDS +				ARDS	ARDS
apoprotein	Normal	ARDS	Normal	At risk	ARDS	Normal	ARDS	PNEU	PNEU	Normal	At risk	(day 1)	(day 14)
SP-A (μg/ml)	2.74	1.49	123.64	49.28^***	29.88^***	1.533	0.849^*	0.747^**	0.876^**	4.813	1.200^***	1.224^***	1.132^***
SP-B (ng/ml)	n.m.	n.m.	1.28	0.89	0.57^***	740	867	818	737	109.5	44.3^***	37.2^***	31.4^***
SP-D (μg/ml)	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	1.034	0.868	1.080	1.220

^aBALF was centrifuged for cell removal; concentration is indicated for original lavage fluid. ^bCell-free BALF was concentrated by centrifugation at 48,000 × g; concentration is indicated for 'crude surfactant pellet'. Values are means. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. BALF = bronchoalveolar lavage fluid; n.m. = not measured; PNEU = pneumonia; SP-A/B/D = surfactant apoprotein A/B/D.

ISSN: 1465-993X